• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 CT 的肿瘤内异质性定量分析预测非小细胞肺癌新辅助免疫化疗的病理完全缓解。

CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.

机构信息

Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.

出版信息

Front Immunol. 2024 Jun 12;15:1414954. doi: 10.3389/fimmu.2024.1414954. eCollection 2024.

DOI:10.3389/fimmu.2024.1414954
PMID:38933281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11199789/
Abstract

OBJECTIVES

To investigate the prediction of pathologic complete response (pCR) in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherapy (NAIC) using quantification of intratumoral heterogeneity from pre-treatment CT image.

METHODS

This retrospective study included 178 patients with NSCLC who underwent NAIC at 4 different centers. The training set comprised 108 patients from center A, while the external validation set consisted of 70 patients from center B, center C, and center D. The traditional radiomics model was contrasted using radiomics features. The radiomics features of each pixel within the tumor region of interest (ROI) were extracted. The optimal division of tumor subregions was determined using the K-means unsupervised clustering method. The internal tumor heterogeneity habitat model was developed using the habitats features from each tumor sub-region. The LR algorithm was employed in this study to construct a machine learning prediction model. The diagnostic performance of the model was evaluated using criteria such as area under the receiver operating characteristic curve (AUC), accuracy, specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV).

RESULTS

In the training cohort, the traditional radiomics model achieved an AUC of 0.778 [95% confidence interval (CI): 0.688-0.868], while the tumor internal heterogeneity habitat model achieved an AUC of 0.861 (95% CI: 0.789-0.932). The tumor internal heterogeneity habitat model exhibits a higher AUC value. It demonstrates an accuracy of 0.815, surpassing the accuracy of 0.685 achieved by traditional radiomics models. In the external validation cohort, the AUC values of the two models were 0.723 (CI: 0.591-0.855) and 0.781 (95% CI: 0.673-0.889), respectively. The habitat model continues to exhibit higher AUC values. In terms of accuracy evaluation, the tumor heterogeneity habitat model outperforms the traditional radiomics model, achieving a score of 0.743 compared to 0.686.

CONCLUSION

The quantitative analysis of intratumoral heterogeneity using CT to predict pCR in NSCLC patients undergoing NAIC holds the potential to inform clinical decision-making for resectable NSCLC patients, prevent overtreatment, and enable personalized and precise cancer management.

摘要

目的

利用术前 CT 图像定量评估肿瘤内异质性,探讨预测接受新辅助免疫化疗(NAIC)的非小细胞肺癌(NSCLC)患者病理完全缓解(pCR)的能力。

方法

本回顾性研究纳入了在 4 个不同中心接受 NAIC 的 178 例 NSCLC 患者。训练集包括中心 A 的 108 例患者,外部验证集由中心 B、中心 C 和中心 D 的 70 例患者组成。通过比较传统放射组学模型和放射组学特征,利用感兴趣区(ROI)内肿瘤的每个像素的放射组学特征,采用 K 均值无监督聚类方法确定肿瘤亚区的最佳划分,利用每个肿瘤亚区的特征建立肿瘤内部异质性生境模型。本研究采用逻辑回归(LR)算法构建机器学习预测模型,使用受试者工作特征曲线下面积(AUC)、准确率、特异度、敏感度、阳性预测值(PPV)和阴性预测值(NPV)等标准评估模型的诊断性能。

结果

在训练队列中,传统放射组学模型的 AUC 为 0.778[95%置信区间(CI):0.688-0.868],而肿瘤内部异质性生境模型的 AUC 为 0.861(95%CI:0.789-0.932)。肿瘤内部异质性生境模型具有更高的 AUC 值,其准确率为 0.815,高于传统放射组学模型的 0.685。在外部验证队列中,两个模型的 AUC 值分别为 0.723(CI:0.591-0.855)和 0.781(95%CI:0.673-0.889),生境模型的 AUC 值仍然较高。在准确性评估方面,肿瘤异质性生境模型优于传统放射组学模型,得分为 0.743,而传统放射组学模型得分为 0.686。

结论

利用 CT 对肿瘤内异质性进行定量分析,预测接受新辅助免疫化疗的 NSCLC 患者的 pCR,可能有助于为可切除 NSCLC 患者的临床决策提供信息,防止过度治疗,并实现个体化和精准的癌症管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/b07e0e1e6481/fimmu-15-1414954-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/6aa4fc64006a/fimmu-15-1414954-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/b00cb3a0148d/fimmu-15-1414954-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/c561f57d3737/fimmu-15-1414954-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/61db510512f9/fimmu-15-1414954-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/c3f2d78f56fa/fimmu-15-1414954-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/b07e0e1e6481/fimmu-15-1414954-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/6aa4fc64006a/fimmu-15-1414954-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/b00cb3a0148d/fimmu-15-1414954-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/c561f57d3737/fimmu-15-1414954-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/61db510512f9/fimmu-15-1414954-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/c3f2d78f56fa/fimmu-15-1414954-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ec/11199789/b07e0e1e6481/fimmu-15-1414954-g006.jpg

相似文献

1
CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.基于 CT 的肿瘤内异质性定量分析预测非小细胞肺癌新辅助免疫化疗的病理完全缓解。
Front Immunol. 2024 Jun 12;15:1414954. doi: 10.3389/fimmu.2024.1414954. eCollection 2024.
2
[F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study.[F]利用氟代脱氧葡萄糖正电子发射断层扫描-计算机断层扫描影像组学特征预测非小细胞肺癌新辅助化疗免疫治疗的病理完全缓解:一项多中心研究
Eur Radiol. 2024 Jul;34(7):4352-4363. doi: 10.1007/s00330-023-10503-8. Epub 2023 Dec 21.
3
A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.联合使用治疗前 CT 影像组学和非小细胞肺癌临床病理特征预测新辅助化疗免疫治疗后的主要病理反应模型。
Curr Probl Cancer. 2024 Jun;50:101098. doi: 10.1016/j.currproblcancer.2024.101098. Epub 2024 May 4.
4
Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study.多模态 CT 深度学习标志物无创预测新辅助免疫化疗后非小细胞肺癌的病理完全缓解:一项多中心研究。
J Immunother Cancer. 2024 Sep 3;12(9):e009348. doi: 10.1136/jitc-2024-009348.
5
CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.基于 CT 放射组学的非小细胞肺癌 TMB 及免疫治疗反应预测模型
BMC Med Imaging. 2024 Feb 15;24(1):45. doi: 10.1186/s12880-024-01221-8.
6
Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study.基于机器学习对非小细胞肺癌新辅助化疗后病理反应和预后的预测:一项回顾性研究
Clin Lung Cancer. 2024 Jul;25(5):468-478.e3. doi: 10.1016/j.cllc.2024.04.006. Epub 2024 Apr 12.
7
Development and Validation of Contrast-Enhanced CT-Based Deep Transfer Learning and Combined Clinical-Radiomics Model to Discriminate Thymomas and Thymic Cysts: A Multicenter Study.基于增强 CT 的深度迁移学习与联合临床放射组学模型在鉴别胸腺瘤和胸腺囊肿中的建立与验证:一项多中心研究。
Acad Radiol. 2024 Apr;31(4):1615-1628. doi: 10.1016/j.acra.2023.10.018. Epub 2023 Nov 10.
8
Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy.基于瘤内和瘤周特征的放射组学模型用于预测接受新辅助免疫化疗的非小细胞肺癌的主要病理反应
Front Oncol. 2024 Mar 20;14:1348678. doi: 10.3389/fonc.2024.1348678. eCollection 2024.
9
Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.基于机器学习的放射组学策略预测非小细胞肺癌细胞增殖。
Eur J Radiol. 2019 Sep;118:32-37. doi: 10.1016/j.ejrad.2019.06.025. Epub 2019 Jun 28.
10
Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.德尔塔放射组学特征预测非小细胞肺癌新辅助化疗免疫治疗的主要病理反应。
Eur Radiol. 2024 Apr;34(4):2716-2726. doi: 10.1007/s00330-023-10241-x. Epub 2023 Sep 22.

引用本文的文献

1
Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study.利用多参数MRI影像组学建立HER2过表达乳腺癌新辅助治疗的预测模型:双中心回顾性研究
Front Oncol. 2025 Jul 15;15:1544058. doi: 10.3389/fonc.2025.1544058. eCollection 2025.
2
Integrative habitat analysis and multi-instance deep learning for predictive model of PD-1/PD-L1 immunotherapy efficacy in NSCLC patients: a dual-center retrospective study.整合栖息地分析与多实例深度学习用于非小细胞肺癌患者PD-1/PD-L1免疫治疗疗效预测模型:一项双中心回顾性研究
BMC Med Imaging. 2025 Jul 17;25(1):288. doi: 10.1186/s12880-025-01828-5.
3

本文引用的文献

1
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis.新辅助免疫疗法联合化疗与单纯化疗治疗非小细胞肺癌的疗效和安全性比较:倾向评分与逆概率处理加权分析
Immunotargets Ther. 2023 Nov 11;12:113-133. doi: 10.2147/ITT.S437911. eCollection 2023.
2
Habitat-based radiomics enhances the ability to predict lymphovascular space invasion in cervical cancer: a multi-center study.基于影像组学的研究提高了预测宫颈癌淋巴管间隙浸润的能力:一项多中心研究。
Front Oncol. 2023 Oct 26;13:1252074. doi: 10.3389/fonc.2023.1252074. eCollection 2023.
3
Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer.
基于四种成像模态的多模态放射组学模型用于预测乳腺癌新辅助治疗的病理完全缓解
BMC Cancer. 2025 Jun 2;25(1):985. doi: 10.1186/s12885-025-14407-2.
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.
纳武利尤单抗联合化疗对比化疗用于可切除 NSCLC 患者的新辅助治疗:CheckMate 816 研究中中国患者的亚组分析。
ESMO Open. 2023 Dec;8(6):102040. doi: 10.1016/j.esmoop.2023.102040. Epub 2023 Nov 1.
4
Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.IB-IV 期 NSCLC 免疫治疗应答者预测的预处理放射组学生物标志物:一项多中心回顾性研究(LCDigital-IO 研究)。
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007369.
5
Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.德尔塔放射组学特征预测非小细胞肺癌新辅助化疗免疫治疗的主要病理反应。
Eur Radiol. 2024 Apr;34(4):2716-2726. doi: 10.1007/s00330-023-10241-x. Epub 2023 Sep 22.
6
Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.利用放射组学特征预测 IB-III 期非小细胞肺癌患者新辅助或转化化疗免疫治疗的病理反应。
Thorac Cancer. 2023 Oct;14(28):2869-2876. doi: 10.1111/1759-7714.15052. Epub 2023 Aug 19.
7
MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer.基于 MRI 的肿瘤内异质性定量分析预测乳腺癌新辅助化疗的治疗反应。
Radiology. 2023 Jul;308(1):e222830. doi: 10.1148/radiol.222830.
8
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.基于放射组学的Nomogram 模型预测潜在可切除的非小细胞肺癌患者新辅助免疫化疗主要病理缓解的开发和验证。
Front Immunol. 2023 Feb 16;14:1115291. doi: 10.3389/fimmu.2023.1115291. eCollection 2023.
9
Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody.空间多组学揭示了肿瘤生态系统异质性对接受双特异性抗体治疗的晚期非小细胞肺癌患者免疫治疗疗效的影响。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006234.
10
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法:进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.